Anti-Human GM-CSF (Clone 3209) - 500 µg

ICC, N, WB

GM-CSF

Next Day Ambient

Granulocyte-Macrophage Colony Stimulating Factor is a 22 kD, pleiotropic cytokine that is a white blood cell growth factor. It controls the production and function of blood cells by stimulating stem cells to produce granulocytes and monocytes. GM-CSF differs from G-CSF in that it affects more cell types including macrophages and eosinophils. Moreover, GM-CSF is part of the immune/inflammatory cascade, a process crucial for fighting infection. Interestingly, GM-CSF expression may have pathological implications. Autocrine expression of GM-CSF in myeloid leukemia cells is suspected to play a role in neoplasia, the formation of a new and abnormal growth of tissue. Additionally, GM-CSF expression has also been documented in certain solid tumors. There have also been reports of GM-CSF in synovial fluid from patients with arthritis suggesting that GM-CSF may play a role in tissue damage associated with the inflammatory process. Blocking GM-CSF is thought to have therapeutic potential by reducing inflammation. Some drugs are currently being developed to block GM-CSF.

Neutralization: This antibody is useful for neutralization of Human GM-CSF bioactivity. The antibody dose required to neutralize 50% (ND₅₀) of the biological activity of Human GM-CSF (at 0.5 ng/ml) is 0.3 - 0.5 µg/ml.
Immunocytochemistry: Suitable for use at concentration of 8-25 µg/mL.

Clone 3209 recognizes an epitope on human GM-CSF. In direct ELISAs, this antibody exhibits less than 15% cross-reactivity with rmGM-CSF.

This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.4 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.